AsymBio Named 'Integrated Biologics CDMO Company of the Year in APAC 2026'

International pharmaceutical media Life Sciences Review APAC exclusively named AsymBio the 'Integrated Biologics CDMO Company of the Year in APAC 2026' and included it in the 'Top CDMO in APAC' list, recognizing its one-stop biologics CDMO capabilities across antibodies and ADCs.

Life Sciences Review APAC, an international pharmaceutical industry media outlet, has named AsymBio (Kaileiying Biologics / AsymBio) the exclusive 'Integrated Biologics CDMO Company of the Year in APAC 2026' and included it among the 'Top CDMO in APAC' list. The award recognizes leading enterprises excelling in technological innovation, biopharma services, global compliance, commercial delivery and industry influence.

Leveraging the group's synergies, AsymBio has built an end-to-end, one-stop biologics CDMO service covering next-generation biologics — from antibodies and bispecific antibodies to ADCs — spanning candidate assessment, process development, manufacturing and regulatory filing.

Through its AccPCC early-stage R&D acceleration platform, AsymBio bridges early research, non-clinical and clinical development. Its dual-site manufacturing layout in Jinshan and Fengxian, Shanghai provides capacity from early R&D and toxicology batches through clinical samples to commercial-scale manufacturing. The quality management system complies with NMPA, FDA and EMA requirements, and all project IP rights are fully retained by the client.

In an exclusive interview, AsymBio CEO Rui Yang said: 'Leveraging our integrated CDMO service model and AccPCC early-stage R&D acceleration platform, we take a holistic approach to forward-looking pipeline planning, project timelines and risk management, and critical commercialization milestones — helping clients accelerate clinical progression and advance toward successful commercialization.'